Neogenomics (NEO) Free Cash Flow (2010 - 2026)

Neogenomics (NEO) has 17 years of Free Cash Flow data on file, last reported at $11.7 million in Q2 2026.

• Quarterly Free Cash Flow fell 16.18% year-over-year to $11.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$7.4 million (up 61.64% YoY) and the FY2025 annual result came in at -$21.8 million, up 36.02% from the prior year.
• Free Cash Flow grew to $11.7 million in Q2 2026, from -$13.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $14.0 million in Q2 2025 to a low of -$37.3 million in Q1 2022.
• A 5-year average of -$10.3 million and a median of -$8.6 million in 2022 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 1620.76% in 2025, down 262.87% in 2025.
• Tracing NEO's Free Cash Flow over 5 years: stood at -$8.2 million in 2022, then surged by 230.51% to $10.7 million in 2023, then slumped by 116.77% to -$1.8 million in 2024, then plunged by 262.87% to -$6.5 million in 2025, then surged by 279.84% to $11.7 million in 2026.
• The last three Free Cash Flow figures came in at $11.7 million (Q2 2026), -$13.1 million (Q1 2026), and -$6.5 million (Q4 2025), per Business Quant data.